Jump to:
Shane Bryan is an associate in Ropes & Gray’s antitrust practice group. Shane has extensive experience securing clearance for deals from the Federal Trade Commission (“FTC”) and Department of Justice (“DOJ”), navigating FTC and DOJ investigations, and counseling clients in antitrust conduct litigation.
Prior to joining Ropes & Gray, Shane represented the FTC’s Bureau of Competition in numerous complex antitrust merger reviews and litigations across multiple industries, including matters relating to the oil and gas, technology, consumer goods, and insurance sectors.
Experience
- Represented Signify Health in its sale to CVS Health in an $8 billion transaction. The transaction closed following antitrust review and investigation by the Department of Justice, including a Second Request.
- Represented uniQure N.V. in a licensing agreement worth over $1.6 billon to provide biopharmaceutical company CSL Behring with exclusive global rights to uniQure’s investigational gene therapy for patients with hemophilia B. The transaction closed following antitrust review and investigation by the Federal Trade Commission, including a Second Request.
- Represented Pfizer in its $5.4 billion acquisition of Global Blood Therapeutics (GBT), a biopharmaceutical company specializing in sickle cell disease treatment.
- Advised TPG and Sixth Street Partners in Kaseya’s $6.2 Billion acquisition of Datto.
- Advised TPG in its $2.2 billion acquisition of ClaimsXten from Change Healthcare.
Notable transactions in which Shane has been involved prior to joining the firm include:
- The FTC’s investigation of the proposed $1.37 billion acquisition of Harry’s, Inc. by Edgewell Personal Care Company. Edgewell abandoned the acquisition after the FTC issued an administrative complaint and requested a temporary restraining order in the U.S. District Court for the District of Columbia.
- The FTC’s investigation of the proposed $1.2 billion acquisition of Stewart Information Services Corporation by Fidelity National Financial, Inc. The parties abandoned the deal after the FTC filed an administrative complaint seeking to block the acquisition.